Clinical Trial Update: ARISE - Aggressive Reduction of Inflammation Stops Events [Phase 3]

View source ↗

Summary

Phase 3 trial ARISE evaluating aggressive reduction of inflammation to stop events in patients with atherosclerosis and coronary artery disease; current status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease
• Myocardial Infarction
• Unstable Angina

Snippet

Sponsor: AtheroGenics | Conditions: Atherosclerosis, Coronary Artery Disease | Phase 3 | Status: UNKNOWN